HomeFilePharmacology

Pharmacology

Olive Oil and Cardiovascular Risk: The Higher the Consumption, the Lower the Risk?

High olive oil intake was associated with lower risk of coronary heart disease and cardiovascular disease in...

The FDA Approves Ticagrelor for Primary Prevention in High Risk Patients

The FDA has approved the indication of ticagrelor as primary prevention in high risk CAD patients with...

Optimal Intervention Timing for NSTEMI with No Antiaggregant Pre-Treatment

Patients undergoing non-ST elevation MI (NSTEMI) who are not pre-treated with P2Y12 receptor inhibitors will benefit from...

Estimating the Risk of Infection for Healthcare Personnel

Roughly one out of every 100 healthcare workers at hospitals receiving COVID-19 patients become infected. Statistics are not...

SPARCL: Highly Effective Prevention of New Events with Atorvastatin after a Stroke

In patients with recent stroke or transient ischemic attack, the total number of vascular events prevented by...

Antiaggregation vs. Anticoagulation after Peripheral PCI

The truth is this question has no clear answer and what with do with peripheral stenting is...

Webinar SOLACI – 29/05 – Approach to Antiplatelet Therapy in Acute Coronary Syndrome

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be...

Cerebrovascular Events After TAVR May Be Especially Serious

Stroke events do not seem to be related to valve thrombosis or structural degeneration, but to a...